检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《四川医学》2010年第2期241-242,共2页Sichuan Medical Journal
摘 要:目的研究HCV感染者在病程各阶段外周血T淋巴细胞亚群的变化。方法流式细胞仪检测丙型肝炎患者CD4+、CD8+T淋巴细胞,并将其分为急性期组,慢性期组检测CD4+CD2+5、CD4+CD2-8T淋巴细胞。结果丙型肝炎患者CD4+T细胞降低,CD8+T细胞升高,CD4+/CD8+降低,与对照组差异有统计学意义(P<0.05)。急性期组CD4+CD2+5与正常对照组差异无统计学意义(P>0.05),但CD4+/CD28-T细胞显著高于对照组(P<0.05)、慢性期组CD4++CD25+T细胞显著增高,而CD4+CD2-8T细胞显著低于对照组(P<0.05)。结论丙型肝炎患者CD4+/CD8+明显降低,机体免疫状态紊乱,在各病程阶段CD4+CD25+、CD4+CD28-T细胞比率明显变化,说明此淋巴细胞亚群与丙型肝炎的发病及发展有密切关系。Objective The changes of peripheral blood T lymphocyte subsets in patients with HCV infection in different courses of disease were studied. Methods Flow cytometry was used to determine the number of CD4^+, CD8^+, CD4^+CD25^+ and CD4^+CD28^-T lymphocyte in patients with HCV infection;and results were analyzed statistically. Results Significantly lower percentage of CD4^+T lymphocyte,and higher of CD8^+ ,with CD4^+/CD8^+ ratio in HCV patients than those in normal control people(P〈 0. 05) ,were demonstrated in the results. It was demonstrate in the result that in the group of patients with acute HCV hepatitis, the percentage of CD4^+ CD25^+ T lymphocyte was near that in control group, but the CD4^+CD28^-T lymphocyte was increased evidently(P 〈0. 05 ), and in the chronic HCV patients group, the percentage of CD4^+CD25^+ T lymphocyte was higher, and the CD4^+ CD28^- lower, significantly(P〈0. 05) than those in control group. Conclusion The results suggest that the ratio of CD4^+/CD8^+T lymphocyte in HCV hepatitis patients is decreased and there is of immune-disorder in these patients. It also suggests that the ratios of CD4^+CD25^+ and CD4^+CD28^-T lymphocyte are of significant changes in acute or chronic HCV hepatitis patients, which means that the changes of these lymphocyte subsest may be of high relationship with the courses of HCV hepatitis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15